Physician profile
Asha Mathews
NPI 1669759841
$4,843.55
in general payments reported to CMS, 2019-2025
38 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $292 · 2023: $954 · 2024: $1,700 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,335.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,534.38 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $362.73 | 2021-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $262.79 | 2023-2025 | Ultomiris |
| Eisai INC. | $189.32 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $187.74 | 2022-2024 | Acthar |
| Lundbeck LLC | $170.81 | 2022-2025 | Vyepti, Rexulti |
| Amgen INC. | $159.39 | 2022-2025 | Uplizna |
| Biogen, INC. | $152.01 | 2021-2025 | Vumerity, Skyclarys |
| Novartis Pharmaceuticals Corporation | $146.31 | 2024 | |
| Grifols USA, LLC | $141.43 | 2023-2025 | Gamunex-C |
| Otsuka America Pharmaceutical, INC. | $140.28 | 2023-2025 | Rexulti |
| Ucb, INC. | $117.33 | 2023-2025 | Rystiggo, Zilbrysq, Fintepla |
| Lilly USA, LLC | $107.62 | 2021-2025 | Emgality, Kisunla, Reyvow |
| Argenx US, INC. | $107.48 | 2025 | Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $97.61 | 2022-2025 | Hyqvia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $91.87 | 2023-2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $79.86 | 2021 | |
| Tanabe Pharma America, INC. | $72.98 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $70.18 | 2024-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $68.29 | 2024-2025 | |
| Neos Therapeutics, Lp | $68.29 | 2023-2024 | Adzenys Xr-Odt |
| Neurelis, INC. | $60.95 | 2024-2025 | Valtoco |
| Celgene Corporation | $58.46 | 2022-2023 | Zeposia |
| Axsome Therapeutics, INC. | $57.02 | 2025 | Symbravo |
| Genentech USA, INC. | $52.38 | 2024-2025 | Ocrevus Zunovo |
| Sk Life Science, INC. | $45.27 | 2022 | |
| Amneal Pharmaceuticals LLC | $39.54 | 2025 | Crexont |
| Impel Pharmaceuticals INC. | $24.76 | 2023 | Trudhesa |
| Corium, LLC | $20.89 | 2023 | Azstarys |
| Horizon Therapeutics Plc | $20.04 | 2023 | |
| Janssen Biotech, INC. | $19.92 | 2025 | |
| Acorda Therapeutics, INC | $19.79 | 2024 | Inbrija |
| Tris Pharma INC | $19.16 | 2023 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $18.45 | 2023 | Quviviq |
| Scilex Pharmaceuticals INC. | $15.74 | 2025 | |
| Ge Healthcare | $14.78 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.17 | 2023 | Qelbree |
| Almatica Pharma LLC | $13.53 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.